Angiogenic proteins as aid in the diagnosis and prediction of preeclampsia

References

• Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–7.
   PubMed Web of Science ®Google Scholar
• Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–99.
   PubMed Web of Science ®Google Scholar
• Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008; 371:261–9.
   PubMed Web of Science ®Google Scholar
• Hofman PL, Regan F, Jackson WE, Jefferies C, Knight DB, Robinson EM, . Premature birth and later insulin resistance. N Engl J Med. 2004;351:2179–86.
   PubMed Web of Science ®Google Scholar
• Irving RJ, Belton NR, Elton RA, Walker BR. Adult cardiovascular risk factors in premature babies. Lancet. 2000;355: 2135–6.
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, . Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–9.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, . Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111:649–58.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Goncalves LF, . Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004;190:1541–7; discussion 7–50.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95:884–91.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, . Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, . Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355: 992–1005.
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–71.
   PubMed Web of Science ®Google Scholar
• Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993;90:10705–9.
   PubMed Web of Science ®Google Scholar
• Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, . Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267:19027–30.
   PubMed Web of Science ®Google Scholar
• Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, . A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005;96:684–92.
   PubMed Web of Science ®Google Scholar
• Parikh SM, Karumanchi SA. Putting pressure on pre-eclampsia. Nat Med. 2008;14:810–2.
   PubMedGoogle Scholar
• Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, . Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004;50:1702–3.
   PubMed Web of Science ®Google Scholar
• Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol. 2003;101:1266–74.
   PubMed Web of Science ®Google Scholar
• Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, . First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89:770–5.
   PubMed Web of Science ®Google Scholar
• Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol. 2001;184:1267–72.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, . Urinary placental growth factor and risk of preeclampsia. JAMA. 2005;293:77–85.
   PubMed Web of Science ®Google Scholar
• Wathen KA, Tuutti E, Stenman UH, Alfthan H, Halmesmaki E, Finne P, . Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab. 2006;91:180–4.
   PubMed Web of Science ®Google Scholar
• Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, . Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50:137–42.
   PubMed Web of Science ®Google Scholar
• Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol. 2007;196:239, e1–6.
   PubMed Web of Science ®Google Scholar
• Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, . The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008;21:279–87.
   PubMed Web of Science ®Google Scholar
• Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol. 2007;197:244, e1–8.
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, . A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med. 2009;22:1021–38.
   PubMed Web of Science ®Google Scholar
• Aggarwal PK, Jain V, Sakhuja V, Karumanchi SA, Jha V. Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int. 2006;69:621–4.
   PubMed Web of Science ®Google Scholar
• Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, . Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol. 2005 Mar;192(3):734–41.
   PubMedGoogle Scholar
• Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007;49:818–24.
   PubMed Web of Science ®Google Scholar
• Stepan H, Geipel A, Schwarz F, Kramer T, Wessel N, Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol. 2008;198:175, e1–6.
   PubMed Web of Science ®Google Scholar
• Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009 May;53(5):812–8.
   PubMedGoogle Scholar
• Levine RJ, Lindheimer MD. First-trimester prediction of early preeclampsia: a possibility at last! Hypertension. 2009;53:747–8.
   PubMed Web of Science ®Google Scholar
• Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 2007;197:28, e1–6.
   PubMedGoogle Scholar
• Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA, . Automated assays for sVEGFR1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol. 2010;202:40, e1–7.
   PubMedGoogle Scholar
• Shan HY, Rana S, Epstein FH, Stillman IE, Karumanchi SA, Williams ME. Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis. Am J Kidney Dis. 2008;51:1029–32.
   PubMedGoogle Scholar
• Signore C, Mills JL, Qian C, Yu K, Lam C, Epstein FH, . Circulating angiogenic factors and placental abruption. Obstet Gynecol. 2006;108:338–44.
   PubMed Web of Science ®Google Scholar
• Signore C, Mills JL, Qian C, Yu KF, Rana S, Karumanchi SA, . Circulating soluble endoglin and placental abruption. Prenat Diagn. 2008;28:852–8.
   PubMed Web of Science ®Google Scholar
• Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, . An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010;202:161, e1–e11.
   PubMedGoogle Scholar
• Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, . Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res. 2010 Epubmed EISSN: 1348–4214.
   Google Scholar